Depomed stock

Why Depomed Inc. Stock Spiked Today. George Budwell | Jan 3, 2017. The drugmaker is reportedly drawing buyout interest from KKR & Co., upping the possibility that a sale is finally imminent. Depomed Inc. Announces Corporate Name Change to Assertio ... In connection with the name change, the Company’s common stock will begin trading under a new ticker symbol “ASRT” and a new CUSIP number, 04545L 107, at the opening of trading today, it has become clear that the name Depomed no longer accurately reflects the business we’re in today or the future direction in which we’re headed.

Assertio reflects an aspirational mindset that is forward thinking, energetic, and entrepreneurial in spirit. The Assertio mission of advancing patient care is reflected in our three-pillar strategy: Why Depomed (DEPO) Stock Is Surging Today | InvestorPlace May 09, 2016 · Depomed’s full-year guidancce has been slightly altered, moving from in the range of $485 million to $525 million, to the range of $490 million to $520 million. DEPO stock is up 14.7% Monday Assertio Therapeutics Inc., ASRT Quick Chart - (NAS) ASRT ... DepoMed stock price target raised to $8 from $6 at UBS MarketWatch. Monday, December 04, 2017. 05:04 PM ET. Depomed farms out Nucynta sales, will lay off 40% of company MarketWatch. 04:34 PM ET. Depomed to reduce staff by 40%, move headquarters out of California MarketWatch. 04:33 PM ET. The Jury's Still Out On Depomed (NASDAQ:ASRT) | Seeking Alpha

ASRT Stock Price, Forecast & News (Depomed) | MarketBeat

Assertio Therapeutics Inc., ASRT Quick Chart - (NAS) ASRT ... DepoMed stock price target raised to $8 from $6 at UBS MarketWatch. Monday, December 04, 2017. 05:04 PM ET. Depomed farms out Nucynta sales, will lay off 40% of company MarketWatch. 04:34 PM ET. Depomed to reduce staff by 40%, move headquarters out of California MarketWatch. 04:33 PM ET. The Jury's Still Out On Depomed (NASDAQ:ASRT) | Seeking Alpha May 21, 2018 · Depomed CEO Arthur Higgins. Depomed delivered a Q1 revenue growth of 42% and EPS growth of over 200%.Growth was spurred by $84 million in revenue from Depomed's recent commercialization agreement with DEPO Stock Quote of Depomed Inc - InvestorPlace

DEPO: DepoMed, Inc. Stock - Real Investment Advice

Check out our DEPO stock analysis, current DEPO quote, charts, and historical prices for Depomed Inc stock Stock Quote | Assertio Therapeutics, Inc. The Investor Relations website contains information about Assertio Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. Depomed Stock Quote. DMI - Stock Price, News, Charts ... Depomed (DMI) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more. Depomed (NYSE:ASRT) Issues Quarterly Earnings Results ...

May 21, 2018 · Depomed CEO Arthur Higgins. Depomed delivered a Q1 revenue growth of 42% and EPS growth of over 200%.Growth was spurred by $84 million in revenue from Depomed's recent commercialization agreement with

Filed: January 14, 2019 as 4:2019cv00255. Court: California Northern District Court Defendant: Depomed, Inc. n/k/a Assertio Therapeutics, Inc., Depomed, Inc.

Why Depomed (DEPO) Stock Is Surging Today | Nasdaq

Formerly known as Depomed, we have transformed our company with a current focus on three FDA-approved products in our core areas of neurology, orphan, 

DepoMed stock price target cut to $51 from $66 at UBS. Aug. 15, 2017 at 9:55 a.m. ET by Tomi Kilgore. DepoMed Q2 rev. $100.4 million vs. expectations $100.1 million. Aug. 7, Assertio Therapeutics We are Assertio — an assertive, energetic, and empathetic pharmaceutical company built around the mission of advancing patient care. Formerly known as Depomed, we have transformed our company with a current focus on three FDA-approved products in our core areas of neurology, orphan, and specialty medicines, as we continue to identify, license, and develop new products that offer enhanced DEPO - Depomed Stock Price - Barchart.com